The gold standard prior to Rituximab approval was CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) [3], and the FDA approved Rituximab as the first-line treatment for DLBCL in 2006 when three phase III trials demonstrated its benefit when added to classical CHOP treatment, with a 2 and 5-year survival rates of 70% and 69% for the R-CHOP, versus 57% and 40% for CHOP alone [3]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.